Enterprise Value

45.83M

Cash

48.51M

Avg Qtr Burn

-25.21M

Short % of Float

6.83%

Insider Ownership

6.01%

Institutional Own.

33.52%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AFM24 (tumor target EGFR) w/ SNK01 & atezolizumab Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

AFM13 (Acimtamig) + AB-101 Details
Lymphoma, Cancer, Hodgkin Lymphoma, peripheral T-cell lymphomas

Phase 2

Data readout

AFM13 (Acimtamig)+ cbNK cells Details
Cancer, Non-Hodgkin lymphoma

Phase 2

Update

AFM13 (Acimtamig) Details
Peripheral T cell cancer , Cancer

Phase 2

Initiation

AFM28 Details
Cancer, Leukemia, Blood cancer, Acute myeloid leukemia

Phase 1

Data readout

AFM24 (tumor target EGFR) Monotherapy Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma, Colorectal cancer

Failed

Discontinued

RO7297089 (formerly AFM26) Details
Multiple myeloma, Cancer

Failed

Discontinued